Overview

Iressa 2nd Line Phase III Study in Japan

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety of gefitinib with docetaxel.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Docetaxel
Gefitinib